NAD+ vs Glow Peptide: What Each One Actually Is

The Short Answer

Glow and NAD+ are not alternatives to one another. Glow is a vendor blend of three peptides, GHK-Cu, BPC-157 and TB-500, sold in one vial. NAD+ is a single coenzyme and not a peptide at all. They share no mechanism, no verification method and no overlapping research literature, so the comparison table below is a contrast rather than a ranking.

	Glow	NAD+
What it is	A blend of three peptides	A single coenzyme, a dinucleotide
Is it a peptide?	Yes, three of them	No
Components	GHK-Cu, BPC-157, TB-500	One molecule
Mechanism studied	Collagen synthesis, angiogenesis, cell migration	Redox electron transfer, substrate for sirtuins and PARPs
Research framing	Tissue repair and dermal matrix	Cellular energy metabolism and aging biology
Peaks a certificate must resolve	Three	Not applicable, different analytical question
Regulatory position	BPC-157 and TB-500 recommended for the 503A list in July 2026, GHK-Cu under review before February 2027	Not part of the 503A peptide nominations

What is Glow, and how does it differ from NAD+?

Glow is a market name for a vial containing GHK-Cu, BPC-157 and TB-500 co-lyophilized together. The name carries no formulation standard, and vendors sell it under numeric designations such as Glow 70 that refer to total milligrams rather than to any agreed ratio.

Each component has its own preclinical literature. GHK-Cu is a copper-binding tripeptide with documented effects on collagen and glycosaminoglycan synthesis in fibroblast culture, and it is the best supported of the three, including human work in topical formulations. BPC-157 is associated with angiogenesis across rodent tendon, ligament and gastrointestinal models. TB-500, a fragment of thymosin beta-4, is associated with actin regulation and cell migration.

What does not exist is any study of the blend itself. The combination has never been tested against its components administered separately. Our Glow peptide overview and stack analysis go through the evidence component by component.

What NAD+ Is, and Why It Is Not a Peptide

NAD+ stands for nicotinamide adenine dinucleotide. As the name indicates it is a dinucleotide: two nucleotides joined through their phosphate groups. A peptide is a chain of amino acids linked by peptide bonds. NAD+ contains neither amino acids nor peptide bonds, which places it in a different chemical family.

It is sold as a peptide because it travels through the same distribution channels. Same lyophilized vial, same bacteriostatic water, same suppliers, same catalogs. The label followed the channel rather than the chemistry.

Functionally, NAD+ is a coenzyme present in every cell, cycling between oxidized and reduced forms to carry electrons through the reactions that produce cellular energy. It is also consumed as a substrate by sirtuins and PARPs, enzyme families involved in DNA repair and gene regulation, which is where most of the aging-related research interest comes from. Our NAD deep dive covers the chemistry, the precursor question and the market in full.

Why These Two Get Compared at All

Given that they share no mechanism, the pairing needs explaining. Three reasons account for almost all of it.

They are shelf neighbors. Vendors list them on the same page, to the same buyers, at broadly similar price points. Adjacency in a catalog generates comparison regardless of chemistry.

Their marketing promises rhyme. Glow is sold around skin, hair and recovery. NAD+ is sold around energy, clarity and aging. Both land in the same aspirational territory even though the underlying arguments are unrelated. We break down sourcing in our guide to NAD+ injections online.

They are often discussed as a pair. A recurring pattern in community posts is running one alongside the other, which produces exactly the kind of question that ends up in search results and in Google’s People Also Ask box.

None of this makes them alternatives to each other. Comparing them is closer to comparing a structural material to a fuel than to comparing two competing products.

Verification Works Differently for Each

The two demand different documents. For Glow, a certificate is only meaningful if it reports each of the three components separately by HPLC and confirms all three molecular weights by mass spectrometry; a single purity figure for the vial is uninformative. For NAD+, verification is simpler because it is one defined molecule with a published formula, so identity and purity resolve on one analysis.

This is the part with real practical consequences, and it is where a buyer’s attention is best spent.

For Glow, the question is whether a certificate resolves and quantifies three separate peaks. A single aggregate purity figure for the vial is close to meaningless, because a product reporting 99 percent purity could be almost entirely one of the three components. You want per-component quantification, mass spectrometry identity for each, and a lot number matching the vial.

For NAD+, the peptide certificate template does not apply. There is no amino acid sequence to confirm, so an identity check based on sequence is meaningless here. NAD+ is also markedly hygroscopic and pH sensitive, which makes handling and storage a larger share of the real risk than purity documentation is. A supplier whose NAD+ certificate looks like a copy of their peptide certificate has probably not thought about the difference.

Our certificate of analysis guide covers reading these documents, and the vendor scores rank suppliers on documentation depth.

Better Questions Than Which One Is Better

Because the two are not substitutes, the comparison question has no answer as posed. These are the questions that do have answers:

1. What is the actual research question you are working on? Structural repair and energy metabolism are different problems with different literatures.
2. Does the supplier’s documentation distinguish the two categories? A vendor issuing an identical certificate format for a three-peptide blend and a dinucleotide is not doing the analysis either product needs.
3. What does it cost per milligram of each component? Vial-level prices are not comparable across products with different fill masses. Our price comparison framework covers the normalization.
4. What is the regulatory position of each? Two of Glow’s three components cleared an FDA advisory committee in July 2026 and the third is queued for review before February 2027. NAD+ was not part of those nominations. See our breakdown of the July 2026 vote.

Frequently Asked Questions

What is the difference between NAD and Glow?

Glow is a blend of three peptides, GHK-Cu, BPC-157 and TB-500, studied in the context of tissue repair. NAD+ is a single coenzyme central to cellular energy metabolism and is not a peptide. They share a sales channel, not a mechanism.

Is NAD+ a peptide?

No. It is a dinucleotide, containing no amino acids and no peptide bonds. It is marketed within the peptide category because it is sold through the same suppliers in the same format.

Can you use Glow and NAD+ together?

They are frequently discussed together, but there is no research on the combination, just as there is none on Glow as a blend. Both are unapproved substances sold as research material.

Which is better for skin?

The dermal argument belongs to GHK-Cu, one of Glow’s three components, which has the strongest human evidence of anything discussed here, in topical formulations. NAD+ has no comparable dermatological literature. That dermal record is also why GHK-Cu leads our guide to peptides for aging skin.

Which is more expensive?

Vial prices are not comparable directly because fill masses differ. Normalize to cost per milligram of each active component before comparing anything.

Peptide Insider publishes market and regulatory analysis for laboratory professionals. This article is informational and is not medical advice. Compounds discussed here are not approved for human use.

Primary sources

• Pickart L, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways. 2015 (PMID 26236730)
• The potential of GHK as an anti-aging peptide. 2020 (PMID 35083444)
• Microneedle-Mediated Delivery of Copper Peptide Through Skin. 2015 (PMID 25690343)
• A randomized placebo-controlled trial of nicotinamide riboside. 2024 (PMID 37994989)